Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
about
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsEfficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled AnalysisEfficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome.Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetesCanagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Canagliflozin: A Review in Type 2 Diabetes.Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
P2860
Q28069065-3CED8779-3570-428C-89B8-9DA3029CC8F3Q30248634-FD0D57B0-1BB4-4A08-9C66-9360954F7334Q33835824-7B2F8886-FC72-428E-AA8E-174E47798030Q36762696-F554A5E0-6E7A-46DD-BD2F-C7B209048910Q37384827-4927CD9C-67A3-4310-B4AC-B6C52BC65492Q37456313-1BE0B0AF-5A8C-434B-B909-88B1622BA72DQ37623972-D02A162A-CC41-4499-8A07-D0CB7C8A9D1DQ37741752-1CA33CE8-81D2-467F-A96F-D556CC314421Q38573559-898874BD-B024-449F-BCBC-6D4D244B3EDAQ39290337-793E952C-957D-4F89-A3B4-5E438BB40D28Q40081685-BB572802-B2DF-4DF6-8223-DE02FB87F0F7Q40960309-2062FEBB-717A-40FE-8D32-A3E6CDCBE8A3Q47115045-C828E60E-C485-4B51-936B-E1ACC7D555EFQ47316565-34306EF9-E77A-45E6-A102-CFBE60E5D4EBQ47918474-B0D74C61-856C-4F02-AE41-40157DB2127C
P2860
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Efficacy and Safety of Canagli ...... A Randomized, Controlled Trial
@ast
Efficacy and Safety of Canagli ...... A Randomized, Controlled Trial
@en
type
label
Efficacy and Safety of Canagli ...... A Randomized, Controlled Trial
@ast
Efficacy and Safety of Canagli ...... A Randomized, Controlled Trial
@en
prefLabel
Efficacy and Safety of Canagli ...... A Randomized, Controlled Trial
@ast
Efficacy and Safety of Canagli ...... A Randomized, Controlled Trial
@en
P2093
P2860
P50
P1433
P1476
Efficacy and Safety of Canagli ...... A Randomized, Controlled Trial
@en
P2093
David R Matthews
Dick de Zeeuw
Frank Vercruysse
Gary Meininger
George Capuano
Greg Fulcher
Mehul Desai
Robert Weiss
Vlado Perkovic
Wayne Shaw
P2860
P2888
P304
P356
10.1007/S13300-015-0117-Z
P577
2015-06-17T00:00:00Z